Literature DB >> 10861085

The role of the CC chemokine, RANTES, in acute lung allograft rejection.

J A Belperio1, M D Burdick, M P Keane, Y Y Xue, J P Lynch, B L Daugherty, S L Kunkel, R M Strieter.   

Abstract

Lung transplantation is a therapeutic option for patients with end-stage lung disease. Acute allograft rejection is a major complication of lung transplantation and is characterized by the infiltration of activated mononuclear cells. The specific mechanisms that recruit these leukocytes have not been fully elucidated. The CC chemokine, RANTES, is a potent mononuclear cell chemoattractant. In this study we investigated RANTES involvement during acute lung allograft rejection in humans and in a rat model system. Patients with allograft rejection had a 2.3-fold increase in RANTES in their bronchoalveolar lavages compared with healthy allograft recipients. Rat lung allografts demonstrated a marked time-dependent increase in levels of RANTES compared with syngeneic control lungs. RANTES levels correlated with the temporal recruitment of mononuclear cells and the expression of RANTES receptors CCR1 and CCR5. To determine RANTES involvement in lung allograft rejection, lung allograft recipients were passively immunized with either anti-RANTES or control Abs. In vivo neutralization of RANTES attenuated acute lung allograft rejection and reduced allospecific responsiveness by markedly decreasing mononuclear cell recruitment. These experiments support the idea that RANTES, and the expression of its receptors have an important role in the pathogenesis of acute lung allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861085     DOI: 10.4049/jimmunol.165.1.461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Vedang Londhe; Ying Ying Xue; Kewang Li; Roderick J Phillips; Robert M Strieter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Fas/FasL and perforin/granzyme pathway in acute rejection and diffuse alveolar damage after allogeneic lung transplantation-a human biopsy study.

Authors:  Iris Bittmann; Christian Müller; Jürgen Behr; Jan Groetzner; Lorenz Frey; Udo Löhrs
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

Review 3.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

Review 4.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

5.  What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis.

Authors:  Robert M Strieter
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

Review 6.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

7.  CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection.

Authors:  Vyacheslav Palchevskiy; Ying Ying Xue; Rita Kern; Stephen S Weigt; Aric L Gregson; Sophie X Song; Michael C Fishbein; Cory M Hogaboam; David M Sayah; Joseph P Lynch; Michael P Keane; David G Brooks; John A Belperio
Journal:  JCI Insight       Date:  2019-05-14

8.  Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide.

Authors:  Stavros Garantziotis; Scott M Palmer; Laurie D Snyder; Tonya Ganous; Benny J Chen; Tie Wang; Donald N Cook; David A Schwartz
Journal:  Transplantation       Date:  2007-10-27       Impact factor: 4.939

9.  Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft.

Authors:  R Saggar; D J Ross; R Saggar; D A Zisman; A Gregson; J P Lynch; M P Keane; S Samuel Weigt; A Ardehali; B Kubak; C Lai; D Elashoff; M C Fishbein; W D Wallace; J A Belperio
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

10.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.